IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Avalanche Biotechnologies, Inc. (“Avalanche” or the “Company”) (NASDAQ: AAVL). Investors who purchased or otherwise acquired shares between July 31, 2014 and June 15, 2015, inclusive (the “Class Period”) are encouraged to contact the Firm immediately to discuss their legal options.
If you purchased shares of Avalanche during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company allegedly issued materially false and misleading statements and/or failed to disclose that Phase 2a of the study for its drug AVA-101 was not designed to show any statistical significance between the active and control groups in the secondary endpoints.
If you purchased shares of Avalanche during the Class Period you have until September 8, 2015 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.